Effect of Galantamine on Caregiver Time and Activities of Daily Living in Mild to Moderate Alzheimer's Disease: A 1-Year Prospective Study.
- Author:
Guk Hee SUH
1
;
Hee Yeon JUNG
;
Chang Uk LEE
;
Sang Kyu LEE
;
Nam Jin LEE
;
Jae Hyun KIM
;
Baik Seok KEE
;
Dae Gwan KO
;
Young Hoon KIM
;
In Ja HONG
;
Sungku CHOI
;
Michael GOLD
Author Information
1. Department of Psychiatry, Hallym University College of Medicine, Seoul, Korea. suhgh@chol.com
- Publication Type:Clinical Trial ; Randomized Controlled Trial ; Original Article
- Keywords:
Galantamine;
Caregiver time;
Alzheimer's disease;
Clinical trial;
Prospective study;
Function;
Benefit;
economy;
Burden
- MeSH:
Activities of Daily Living*;
Alzheimer Disease*;
Caregivers*;
Cohort Studies;
Galantamine*;
Humans;
Prospective Studies*
- From:Journal of the Korean Geriatrics Society
2007;11(2):74-82
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study aims to investigate the effect of galantamine on caregiver time and activities of daily living(ADLs) in patients with mild to moderate Alzheimer's disease(AD) in a Korean population. DESIGN: Quasi-experimental study: A rndomized, double-blind, parallel-group clinical trial and a naturalistic longitudinal community study METHOD: For this 1-year prospective study, 138 patients residing in the community were recruited(baseline MMSE score of. 10-22). The two groups were composed of 72 patients treated with galantamine and 66 patients selected as the control group from an untreated community cohort of AD patients. The primary efficacy outcome was the caregiver time and the secondary efficacy measure was the Korean version of the Disability Assessment for Dementia(DAD-K) scale. RESULTS: The results of a mixed model analyses demonstrated reduced caregiver time and improved ADLs in galantamine group relative to baseline and compared with the community control group in this 1-year prospective study. Significant improvement in galantamine group observed in the DAD scores demonstrated beneficial effects of galantamine on delaying functional deterioration in patients with mild to moderate AD. Difference in caregiver time between two groups was equivalent to additional 9.5 working days per month or 113 working days per year. CONCLUSION: Treatment with Galantamine is associated with a significantly slower decline in basic and instrumental ADLs in patients with mild to moderated AD. These benefits on functional capacity in patients with AD treated with galantamine were associated with less caregiver time, lower caregiver burden and higher economic benefits.
